ES2654065T3 - Anticuerpo monoclonal anti-tenascina humana - Google Patents

Anticuerpo monoclonal anti-tenascina humana Download PDF

Info

Publication number
ES2654065T3
ES2654065T3 ES05718988.8T ES05718988T ES2654065T3 ES 2654065 T3 ES2654065 T3 ES 2654065T3 ES 05718988 T ES05718988 T ES 05718988T ES 2654065 T3 ES2654065 T3 ES 2654065T3
Authority
ES
Spain
Prior art keywords
antibody
tenascin
antibodies
biotinylated
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05718988.8T
Other languages
English (en)
Spanish (es)
Inventor
Rita De Santis
Angela Pelliccia
Giovanna Palombo
Paolo Carminati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfasigma SpA
Original Assignee
Alfasigma SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfasigma SpA filed Critical Alfasigma SpA
Application granted granted Critical
Publication of ES2654065T3 publication Critical patent/ES2654065T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES05718988.8T 2004-02-27 2005-02-16 Anticuerpo monoclonal anti-tenascina humana Expired - Lifetime ES2654065T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000105A ITRM20040105A1 (it) 2004-02-27 2004-02-27 Anticorpo monoclonale antitenascina umana.
ITRM20040105 2004-02-27
PCT/IT2005/000078 WO2005082938A2 (en) 2004-02-27 2005-02-16 Anti-human tenascin monoclonal antibody

Publications (1)

Publication Number Publication Date
ES2654065T3 true ES2654065T3 (es) 2018-02-12

Family

ID=34897820

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05718988.8T Expired - Lifetime ES2654065T3 (es) 2004-02-27 2005-02-16 Anticuerpo monoclonal anti-tenascina humana

Country Status (15)

Country Link
US (1) US7989171B2 (enExample)
EP (1) EP1718678B1 (enExample)
JP (1) JP5191036B2 (enExample)
KR (1) KR101266389B1 (enExample)
CN (1) CN1946740B (enExample)
AR (1) AR047819A1 (enExample)
AU (1) AU2005217237B2 (enExample)
BR (1) BRPI0508082A8 (enExample)
CA (1) CA2558718C (enExample)
ES (1) ES2654065T3 (enExample)
IT (1) ITRM20040105A1 (enExample)
MX (1) MXPA06009674A (enExample)
PL (1) PL1718678T3 (enExample)
PT (1) PT1718678T (enExample)
WO (1) WO2005082938A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006086769A2 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2012031084A (ja) * 2010-07-29 2012-02-16 Tokyo Univ Of Science 抗腫瘍剤
WO2014113459A1 (en) * 2013-01-15 2014-07-24 Duke University Hiv-1 neutralizing factor
EP2999967B1 (en) 2013-05-21 2020-05-20 NX Pharmagen Use of tenascin-c as an extracellular marker of tumor-derived microparticles
GB201414021D0 (en) * 2014-08-07 2014-09-24 Nascient Ltd Biological materials and uses thereof
GB201616596D0 (en) * 2016-09-29 2016-11-16 Nascient Limited Epitope and antibodies
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
CN119019548B (zh) * 2022-07-05 2025-06-24 东莞市朋志生物科技有限公司 抗甲型流感病毒抗体、检测甲型流感病毒的试剂和试剂盒

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5634076A (en) * 1994-10-04 1997-05-27 Analog Devices, Inc. DMA controller responsive to transition of a request signal between first state and second state and maintaining of second state for controlling data transfer
US6014709A (en) * 1997-11-05 2000-01-11 Unisys Corporation Message flow protocol for avoiding deadlocks
US6335014B1 (en) * 1998-06-17 2002-01-01 The Institute Of Physical And Chemical Research Medicament for suppressing cancer metastasis
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
AU4682100A (en) * 1999-05-01 2000-11-17 University Of Medicine And Dentistry Of New Jersey Neurite outgrowth and guidance by tenascin-c
US7058750B1 (en) * 2000-05-10 2006-06-06 Intel Corporation Scalable distributed memory and I/O multiprocessor system
JP3646159B2 (ja) * 2001-02-08 2005-05-11 国立大学法人三重大学 抗テネイシンｃモノクローナル抗体及び当該抗体を産生するハイブリドーマ
ITRM20010079A1 (it) * 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti Amminoderivati della biotina e loro coniugati con chelanti macrociclici.
SI1478667T1 (sl) * 2002-02-26 2010-12-31 Sigma Tau Ind Farmaceuti Monoklonski protitelesni anti-äśloveĺ ki tenascin
ITRM20020128A1 (it) * 2002-03-08 2003-09-08 Sigma Tau Ind Farmaceuti Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting".

Also Published As

Publication number Publication date
WO2005082938A2 (en) 2005-09-09
HK1100848A1 (en) 2007-09-28
EP1718678B1 (en) 2017-10-11
WO2005082938A3 (en) 2005-12-15
AU2005217237A1 (en) 2005-09-09
KR101266389B1 (ko) 2013-05-28
CA2558718C (en) 2015-01-13
ITRM20040105A1 (it) 2004-05-27
AU2005217237B2 (en) 2011-12-22
JP5191036B2 (ja) 2013-04-24
BRPI0508082A (pt) 2007-07-17
PL1718678T3 (pl) 2018-05-30
CN1946740A (zh) 2007-04-11
CA2558718A1 (en) 2005-09-09
KR20070002029A (ko) 2007-01-04
US7989171B2 (en) 2011-08-02
JP2008506355A (ja) 2008-03-06
MXPA06009674A (es) 2007-03-21
BRPI0508082A8 (pt) 2017-12-26
PT1718678T (pt) 2017-12-29
US20100297003A1 (en) 2010-11-25
CN1946740B (zh) 2012-09-05
AR047819A1 (es) 2006-02-22
EP1718678A2 (en) 2006-11-08

Similar Documents

Publication Publication Date Title
ES2910407T3 (es) Anticuerpos anti-CD71 activables y procedimientos de uso de los mismos
ES2881886T3 (es) Anticuerpos dirigidos a HER-3 y sus usos
US7378091B2 (en) Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
EP0753015B1 (en) Monoclonal antibodies recognizing tie-receptor and their use
DK172440B1 (da) Monoklonale antistoffer og derivater deraf, fremgangsmåde til deres fremstilling, hybridomacellelinie og fremgangsmåde til
ES2742287T3 (es) Anticuerpos monoclonales contra el factor de diferenciación de crecimiento 15 (GDF-15)
ES2363891T3 (es) Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
ES2197217T3 (es) Anticuerpo 3h1 monoclonal anti-id-murino.
ES2754774T3 (es) Profilaxis de cáncer colorrectal y gastrointestinal
ES2743913T3 (es) Anticuerpos contra el antígeno 1 asociado al riñón y fragmentos de unión al antígeno de los mismos
ES2654065T3 (es) Anticuerpo monoclonal anti-tenascina humana
CN101022830A (zh) 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途
ES2788159T3 (es) Sialil-di-Lewisa tal como se expresa en las glucoproteínas pero no en los glucolípidos como diana funcional del cáncer y sus anticuerpos
Petronzelli et al. Improved tumor targeting by combined use of two antitenascin antibodies
PT1718737E (pt) Anticorpos que modificam doenças cancerosas
Luiten et al. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients
ES2306677T3 (es) Procedimiento para la produccion de anticuerpos anticancerosos citotoxicos.
Van Gog et al. Rapid elimination of mouse/human chimeric monoclonal antibodies in nude mice
Gerretsen et al. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F (ab') 2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG
WO2025040093A1 (zh) 靶向gpc3的分子探针以及用途
ES2284493T3 (es) Anticuerpo monoclonal dirigido contra las celulas de carcinoma renal humano.
Xiang et al. Production and characterization of a tumor-specific monoclonal antibody ACT19 recognizing an epitope distinctive from sialosyl-Tn on the TAG72 antigen
WO2025131054A1 (en) Antibody drug conjugates targeting to b7-h3 and egfr and the use thereof
FI111267B (fi) Tie-reseptoria tunnistavat vasta-aineet ja niiden käyttö
Balm et al. Carcinoma-associated monoclonal antibodies in head and neck carcinoma: immunohistochemistry and biodistribution of monoclonal antibodies 175F4 and 175F11